150 results on '"Micevic, Goran"'
Search Results
2. Clinical and Histologic Variants of CD8+ Cutaneous T-Cell Lymphomas.
3. Cutaneous diatoms from diatomaceous earth mimicking myiasis infection
4. KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements
5. RAP80 and BRCA1 PARsylation protect chromosome integrity by preventing retention of BRCA1-B/C complexes in DNA repair foci
6. 1025 Tumor-specific CD8+ T cells epigenetically licensed by IL-7R are critical for anti-tumor immunity in melanoma
7. Melanoma tumour-infiltrating T-lymphocyte therapy heralds the era of cell-based immunotherapies for solid tumours.
8. New insights into PD-1 blockade associated cutaneous immune-related adverse events
9. IL-7R licenses a population of epigenetically poised memory CD8 + T cells with superior antitumor efficacy that are critical for melanoma memory
10. Setdb1-loss induces type-I interferons and immune clearance of melanoma
11. ISID1234 - Immunotherapy induces clonal expansion of cytotoxic tumor-specific TILs in a model of melanoma
12. p90RSK Blockade Inhibits Dual BRAF and MEK Inhibitor-Resistant Melanoma by Targeting Protein Synthesis
13. Supplemental Figure 7 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume
14. Supplemental Figure 1 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume
15. Data from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume
16. Supplemental Figure 9 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume
17. Supplemental Figure 5 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume
18. Supplemental Figure 4 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume
19. Supplemental Figure 2 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume
20. Supplemental Figure 6 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume
21. Supplemental Figure 3 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume
22. Supplemental Table 1 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume
23. Supplemental Figure 8 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume
24. Supplemental Figure Legends from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume
25. The Crossroads of Cancer Epigenetics and Immune Checkpoint Therapy
26. Erythrodermic scabies in an immunocompetent patient
27. Leukoderma Induced by Rotigotine Patch, a Transdermal Dopamine Agonist
28. IL-7R licenses a population of epigenetically poised memory CD8+ T cells with superior antitumor efficacy that are critical for melanoma memory.
29. Abstract 1380: Setdb1-loss reactivates ERV expression and interferon signaling to induce immune-mediated melanoma clearance
30. New insights into programmed cell death protein 1 blockade-associated cutaneous immune-related adverse events.
31. Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid Tumors
32. Integrative discovery of CD98 as a melanoma biomarker
33. Perniolike lesions and coagulopathy in a patient with COVID-19 infection
34. Ablation of Histone Demethylase KDM5B in Melanoma Augments Anti-Tumor Immunity through Upregulation of Retroelements
35. Structure-Guided Identification of DNMT3B Inhibitors
36. PD‐L1 methylation regulates PD‐L1 expression and is associated with melanoma survival
37. Inhibition of isoprenylation synergizes with MAPK blockade to prevent growth in treatment‐resistant melanoma, colorectal, and lung cancer
38. Balanitis associated with FOLFIRI chemotherapy
39. Additional file 2: of Genome-wide characterization of human L1 antisense promoter-driven transcripts
40. UV-induced somatic mutations elicit a functional T cell response in the YUMMER1.7 mouse melanoma model
41. (S029) Development of an Immune-Associated Molecular Signature Predicting Melanoma Survival
42. Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities
43. Histone demethylase KDM5B is critical for PI3K‐AKT‐mTOR signaling and stemness of melanoma
44. Attenuation of genome-wide 5-methylcytosine level is an epigenetic feature of cutaneous malignant melanomas
45. PD‐L1 methylation regulates PD‐L1 expression and is associated with melanoma survival.
46. Inhibition of isoprenylation synergizes with MAPK blockade to prevent growth in treatment‐resistant melanoma, colorectal, and lung cancer.
47. The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations
48. Abstract 2768: Global DNA hypomethylation is an important feature of melanoma
49. Genome-wide characterization of human L1 antisense promoter-driven transcripts
50. Cell and Tissue Display
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.